Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome

17 Nov 2021

Abstract excerpt

Down syndrome (DS) is a complex genetic disorder associated with substantial physical, cognitive, and behavioral challenges. Due to better treatment options for the physical co-morbidities of DS, the life expectancy of individuals with DS is beginning to approach that of the general population. However, the cognitive deficits seen in individuals with DS still cannot be addressed pharmacologically. In young...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down syndrome and intellectual disability research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34832952
DOI: 10.3390/ph14111170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down SyndromePMID 34832952Read ↗

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down SyndromeSemantic proximity Read ↗

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down SyndromeSemantic proximity Read ↗

Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer’s?Semantic proximity Read ↗

Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerationsSemantic proximity Read ↗

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's DiseaseSemantic proximity Read ↗

LONG-TERM NEURODEVELOPMENTAL AND COGNITIVE OUTCOMES FOLLOWING PRENATAL INHIBITION OF DYRK1A BY LEUCETTINE L41 IN MOUSE MODELS OF DOWN SYNDROMESemantic proximity Read ↗

Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down SyndromeSemantic proximity Read ↗

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp>own syndrome mouse models and in humansSemantic proximity Read ↗

Molecular basis of pharmacotherapies for cognition in Down syndrome.Semantic proximity Read ↗

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directionsSemantic proximity Read ↗

New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down SyndromeSemantic proximity Read ↗

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivativesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.